Breaking Finance News

Zacks Investment Research upgraded T2 Biosystems Inc (NASDAQ:TTOO) to Hold in a report released today.

Zacks Investment Research has upgraded T2 Biosystems Inc (NASDAQ:TTOO) to Hold in a report released on 10/06/2016.

Just yesterday T2 Biosystems Inc (NASDAQ:TTOO) traded -1.67% lower at $7.27. T2 Biosystems Inc’s 50-day moving average is $6.95 and its 200-day moving average is $7.83. The last stock price is down -9.62% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 101,170 shares of TTOO traded hands, down from an average trading volume of 183,200

Recent Performance Chart

T2 Biosystems Inc (NASDAQ:TTOO)

T2 Biosystems Inc has 52 week low of $4.92 and a 52 week high of $12.15 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokerages have issued a ratings update on the company. The average stock price target is $12.71 with 3 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 3 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On T2 Biosystems Inc (NASDAQ:TTOO)

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *